Nanomedicine is the application of nanotechnology to medicine and healthcare. The field takes advantage of the physical, chemical and biological properties of materials at the nanometer scale to be used for a better understanding of the biological mechanisms of diseases at the molecular level, leading to new targets for earlier and more precise diagnostics and therapeutics. Nanomedicine, rated among the six most promising Key Enabling Technologies, is one of the most important emerging areas of health research expected to contribute to one of the strategic challenges that Europe has to face in the future: Provide effective and affordable health care and assure the wellbeing of an increasingly aged population. EuroNanoMed III (ENM III) builds on the foundations of ENM I & II, which launched 7 successful joint calls for proposals since 2009, funded 51 transnational research projects involving 269 partners from 25 countries/regions, and allocated € 45,5 million to research projects from ENM funding agencies. ENM III consortium, reinforced with 12 new partners from Europe, Canada and Taiwan, is committed to fostering the competiveness of European nanomedicine actors taking into account recent changes in the landscape and new stakeholders and challenges, as identified in the SRIA in nanomedicine. The first joint call for proposals will be co-funded by ENM III partners and the EC. After the co-funded call, three additional joint transnational calls will be organized and strategic activities will be accomplished in collaboration with key initiatives in the field. ENM III actions focus on translatability of project results to clinical and industry needs.

QuantERA III is aimed at strengthening Europe’s leadership in Quantum Technologies (QT) through a highly coordinated transnational approach. Building on the success of its predecessors, QuantERA III will subsidise cutting-edge research by launching a Cofunded Call for Proposals in 2025, backed by over €37 M in national contributions, targeting two critical areas: Quantum Phenomena and Resources and Applied Quantum Science. Additional €15 M of the EU contribution shall be allocated to both the Cofunded Call budget and the project tasks. By supporting projects that lay the foundations for future QT advancements and translating quantum science into practical applications, the Programme will catalyse new directions in the field, ensuring the EU’s leading status in this transformative technology sector. QuantERA III’s objectives align seamlessly with the EC’s Work Programme, as it seeks to address fragmentation in QT research across the European Research Area (ERA) and develop synergy in transnational research efforts. QuantERA III is designed to meet the highest standards of excellence, capitalising on the collective expertise and resources of 40 RFOs from 30 countries (incl. 14 Widening countries) – the Programme will achieve its objectives through a well-structured approach that leverages the unique strengths of each Consortium partner. It will explore further funding opportunities, continue mapping QT policies in Europe, address gender imbalance in QT, and – liaising with the Quantum Flagship and other stakeholders – engage with non-European countries to expand its reach and amplify its impact. The Consortium aims to build a sustainable vision for QuantERA beyond Horizon Europe, benefitting the entire ERA by enhancing Europe’s innovation capacity and maintaining its competitive edge on the global stage. Through its comprehensive framework of six Work Packages, the proposal ensures the realisation of its goals, aligning perfectly with the EC’s priorities for R&I.

The ERA-NET Cofund BlueBio will act to unlock the potential of aquatic bio-resources to create jobs, economic growth and provide food, nutrition and bio-based products and services. Thus, paving the way for a sustainable and competitive Blue Bioeconomy in Europe. The goal is to identify new and improve existing ways of bringing bio-based products and services to the market and find new ways of creating value in the Blue bioeconomy. The objectives of BlueBio are to establish a coordinated R&D funding scheme that will strengthen Europe’s position in this complex economic field in a global market. This will primarily be achieved by engaging funding agencies to implement a co-funded call focusing on Blue Knowledge and technological developments to respond to needs and gaps for R&I. The consortium has committed budgets making a strong co-funded call leveraging well the Commission's requests. BlueBio builds upon the networks, achievements and strategies obtained in the COFASP and ERA-MBT ERA-NETs and JPI Oceans, and will leverage the JPI Oceans role as a coordination platform. The consortium aims to implement 2-4 additional calls, developed through stakeholder engagement, and identifying new funding initiatives. BlueBio will implement a range of related activities which can add value to the cofounded projects and better address the impact of R&I projects. BlueBio will enhance valorisation from the actors in the Blue Bioeconomy sector, identify and address R&I needs of industry and society. Communications activities will support BlueBio and the funded projects to realise tangible impacts. Emphasis will be placed on the creation of pre-commercial outputs aimed at accelerating commercialisation and competitive deployment. BlueBio's directions and legacy will be informed by strategic forward-looking processes involving all stakeholders in identifying needs and gaps along the value chains.

Quantum Technologies (QT) is a highly interdisciplinary, paradigm-changing area of research. European researchers have been at the forefront of these developments, delivering many groundbreaking scientific results and advancing technological exploitation. For the past four years, the QuantERA network has been successfully providing the research community with a coordinated Europe-wide approach to support cutting-edge research in QT. Building on this experience, with EU support, the QuantERA consortium (currently present in 30 countries) will continue its activities and develop them even further. The central objective of this proposal is to launch a transnational co-funded call with a planned budget of over €26M of national contributions. €15M of EU contribution is expected to support the co-funded call budget and project tasks. In accordance with the FET Work Programme 2018-2020, the scientific scope of the QuantERA II co-funded call will complement the Quantum Technologies Flagship activities. QuantERA II will seek to effectively liaise with the QT Flagship and other stakeholders in the field of QT research to make the best use of the collective European experience in QT research funding, as well as address the gender imbalance in QT research and spread the research excellence across European Research Area (ERA). A range of additional activities will be integrated into the launch of the co-funded call: strengthening the multilateral dialogue with policy makers regarding the design of future funding instruments, stimulation of networking and exchange of best practices, continuation of mapping of public QT policies in Europe, use of the Guidelines on Responsible Research and Innovation in QT developed in the first QuantERA programme. The QuantERA II proposal conforms to the specific challenges and scope of the Work Programme Horizon 2020-Future and Emerging Technologies by providing a structured framework to coordinate national and regional research programmes in QT.

Antimicrobial resistance (AMR) is a global health challenge with an estimated 67% increase in global deaths attributable to AMR by 2050. The European Partnership One Health AMR (EUP OHAMR) is aiming to reduce the burden of AMR with an integrated One Health (OH) approach, recognising that human, animal and plant health are interdependent and interlinked with the environment. The partnership will boost AMR research and innovation (R&I) addressing the current knowledge gaps with the aim to improve surveillance of resistant pathogens and provide better diagnostics and more effective treatments of drug-resistant infections. It will support implementation research on prevention measures reducing the use of antimicrobials and spread of AMR and launch an ambitious work programme of joint activities to coordinate R&I investments, facilitate the use and re-use of R&I data, strengthen AMR R&I capacities and facilitate both knowledge translation and uptake of research results and innovations by industry, society, and policy makers. The EUP OHAMR builds on the long-standing collaboration of the partners from the Joint Programme Initiative on AMR (JPIAMR) but with a bigger ambition and a broader scope. The partnership consists of 53 partners from 30 countries from the European Union (EU) and beyond. With active engagement of key stakeholders across the AMR landscape, the partnership will strengthen European and global synergies through alignment of research priorities, policies, and investments. Furthermore, EUP OHAMR will support multisectoral and multidisciplinary collaborations to break the existing silos in AMR research. It will result in increased knowledge and solutions and provide an evidence base for uptake into policy and practice to prevent and tackle AMR. Thus, the EUP OHAMR will deliver towards to the priorities set in the European One Health Action plan against AMR, thereby strengthening the European Research and Innovation Area ecosystem and contribute to making the EU a best-practice region on AMR.